We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout
Read MoreHide Full Article
Thermo Fisher, Inc.’s (TMO - Free Report) inorganic expansion strategy gets a new momentum with the company entering into a whopping $17.4-billion deal to acquire PPD, Inc. Thermo Fisher also announced its board of directors’ approval of this definitive acquisition agreement.
The transaction is expected to close by the end of 2021, subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals.
Impact on Stock
Immediately after the rollout of this news, shares of Thermo Fisher rose 3.4% on April 15 to close at $494.38.
A Few Words on PPD
For investors’ note, PPD is a global clinical research organization offering broad, integrated drug development, laboratory and lifecycle management services to help customers accelerate innovation and increase drug development productivity.
In 2020, PPD generated revenue of $4.7 billion. With the acquisition, PPD will get integrated under Thermo Fisher's Laboratory Products and Services segment.
Financial Terms of the Deal
Per terms of the deal, Thermo Fisher will pay $47.50 a share for PPD, and will assume about $3.5 billion of net debt, which represents a premium of around 24% to the unaffected closing price of PPD's common stock on NASDAQ as of Apr 13 or 32% to the 60-day Volume weighted average price inclusive of that date.
The PPD deal is expected to add $1.40 to Thermo Fisher's adjusted earnings per share in the first 12 months after its closure. Overall, the buyout will deliver synergies of $125 million by the third year since the date of completion.
How Strategic is the Deal?
The combination will create one of the biggest drug-testing companies in the United States. The acquisition of PPD is going to expand Thermo Fishers’ global reach in the attractive, high-growth clinical research services industry.
Per Thermo Fisher’s management, the acquisition of PPD is a natural extension for the company and will allow it to provide its customers with vital clinical research services and will enable the company to partner with them in new and exciting ways.
PPD will bring a proven drug development platform, excellent patient recruitment capabilities, strong laboratory services and a complementary reputation for excellent quality and service which will enhance Thermo Fisher's offerings. The combined synergies will further boost Thermo Fisher's value proposition to pharma and biotech customers and allow them to access its services more efficiently.
Recent Notable Acquisitions
In February 2021, Thermo Fisher announced the completion of its previously announced acquisition of Mesa Biotech, Inc. – a privately held point-of-care molecular diagnostic company. The acquisition of Mesa Biotech is an important part of the Thermo Fisher’s strategy to expand the benefits of molecular diagnostics at the point of care, starting with COVID-19 testing.
During the same month, Thermo Fisher acquired cell-sorting technology assets from Propel Labs – a wholly-owned subsidiary of SIDIS Corp. A first of its kind, the Bigfoot Spectral Cell Sorter brings more powerful sorting capabilities and faster throughput, and its novel safety features broaden Thermo Fisher’s already strong flow cytometry offering.
Industry Prospects
Per Grand View Research, the global clinical trials market size was valued at $44.3 billion in 2020 and is expected to reach $69.5 billion by 2028 growing at a CAGR of 5.7%.
Price Performance
Shares of the company have gained 50.7% in a year’s time compared with the industry’s growth of 31.1%.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
Intuitive Surgical has a projected long-term earnings growth rate of 21%.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout
Thermo Fisher, Inc.’s (TMO - Free Report) inorganic expansion strategy gets a new momentum with the company entering into a whopping $17.4-billion deal to acquire PPD, Inc. Thermo Fisher also announced its board of directors’ approval of this definitive acquisition agreement.
The transaction is expected to close by the end of 2021, subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals.
Impact on Stock
Immediately after the rollout of this news, shares of Thermo Fisher rose 3.4% on April 15 to close at $494.38.
A Few Words on PPD
For investors’ note, PPD is a global clinical research organization offering broad, integrated drug development, laboratory and lifecycle management services to help customers accelerate innovation and increase drug development productivity.
In 2020, PPD generated revenue of $4.7 billion. With the acquisition, PPD will get integrated under Thermo Fisher's Laboratory Products and Services segment.
Financial Terms of the Deal
Per terms of the deal, Thermo Fisher will pay $47.50 a share for PPD, and will assume about $3.5 billion of net debt, which represents a premium of around 24% to the unaffected closing price of PPD's common stock on NASDAQ as of Apr 13 or 32% to the 60-day Volume weighted average price inclusive of that date.
The PPD deal is expected to add $1.40 to Thermo Fisher's adjusted earnings per share in the first 12 months after its closure. Overall, the buyout will deliver synergies of $125 million by the third year since the date of completion.
How Strategic is the Deal?
The combination will create one of the biggest drug-testing companies in the United States. The acquisition of PPD is going to expand Thermo Fishers’ global reach in the attractive, high-growth clinical research services industry.
Per Thermo Fisher’s management, the acquisition of PPD is a natural extension for the company and will allow it to provide its customers with vital clinical research services and will enable the company to partner with them in new and exciting ways.
PPD will bring a proven drug development platform, excellent patient recruitment capabilities, strong laboratory services and a complementary reputation for excellent quality and service which will enhance Thermo Fisher's offerings. The combined synergies will further boost Thermo Fisher's value proposition to pharma and biotech customers and allow them to access its services more efficiently.
Recent Notable Acquisitions
In February 2021, Thermo Fisher announced the completion of its previously announced acquisition of Mesa Biotech, Inc. – a privately held point-of-care molecular diagnostic company. The acquisition of Mesa Biotech is an important part of the Thermo Fisher’s strategy to expand the benefits of molecular diagnostics at the point of care, starting with COVID-19 testing.
During the same month, Thermo Fisher acquired cell-sorting technology assets from Propel Labs – a wholly-owned subsidiary of SIDIS Corp. A first of its kind, the Bigfoot Spectral Cell Sorter brings more powerful sorting capabilities and faster throughput, and its novel safety features broaden Thermo Fisher’s already strong flow cytometry offering.
Industry Prospects
Per Grand View Research, the global clinical trials market size was valued at $44.3 billion in 2020 and is expected to reach $69.5 billion by 2028 growing at a CAGR of 5.7%.
Price Performance
Shares of the company have gained 50.7% in a year’s time compared with the industry’s growth of 31.1%.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space include Intuitive Surgical, Inc. (ISRG - Free Report) , Cantel Medical Corp. and ConforMIS, Inc. , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical has a projected long-term earnings growth rate of 21%.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>